Joseph Tyndall Purchases Axogen, Inc. Shares
Joseph Tyndall acquired 4,392 shares of Axogen, Inc. on June 24, 2026.
Key Points
- Joseph Tyndall bought 4,392 shares of Axogen, Inc. on June 24, 2026, with no disclosed transaction value.
- Axogen shares traded near $44.49 on Saturday, with a market cap of about $2.37 billion and a forward P/E of 61.1.
- Analysts have set a mean price target of $50.78 for Axogen, with firms like Canaccord Genuity maintaining buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Joseph Tyndall made a move to increase his stake in Axogen, Inc. (NasdaqCM: AXGN) by purchasing 4,392 shares on June 24, 2026. The transaction did not specify a price or total value. This buy was not part of a pre-planned trading program.
Insider Buying and Selling at Axogen, Inc.
On June 24, 2026, several insiders at Axogen, Inc. bought shares. Joseph Tyndall purchased 4,392 shares, as did Kathy Johnson, Amy McBride Wendell, William Burke, and John Johnson. Paul Thomas acquired 5,579 shares. None of these transactions were made under a Rule 10b5-1 plan.
Other Institutional Activity in Axogen, Inc.
Several institutional investors adjusted their positions in Axogen. First Light Asset Management, LLC reduced its holdings by 1,230,558 shares, bringing its total to 4,002,768 shares valued at about $132.6 million, a 23.5% decrease. BlackRock, Inc. increased its stake by 151,414 shares to 3,870,851 shares, worth approximately $128.2 million, marking a 4.1% increase. Morgan Stanley added 536,112 shares, resulting in a 20.7% increase, now holding 3,122,982 shares valued at $103.5 million. Vanguard Capital Management LLC opened a new position with 2,291,563 shares valued at $75.9 million. Arrowmark Colorado Holdings LLC grew its holdings by 441,157 shares, a 29.9% increase, totaling 1,915,439 shares worth about $63.5 million.
Axogen, Inc. Stock Down 12.7%
Shares of Axogen, Inc. traded around $44.49 on Saturday. The company, with a market cap of approximately $2.37 billion, has a forward P/E ratio of 61.1 and a beta of 1.118. Over the past year, the stock has ranged from a low of $10.20 to a high of $46.00. The 50-day moving average is $41.31, and the 200-day moving average stands at $30.96. Axogen's current ratio is a strong 7.101, with a quick ratio of 4.994 and a debt-to-equity ratio of 8.432.
$AXGN stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Several analysts have maintained their buy ratings for Axogen, Inc. On April 29, 2026, Canaccord Genuity, Citizens, Wells Fargo, and HC Wainwright & Co. all reiterated buy ratings with price targets around $50. Lake Street also maintained its buy rating with a $50 target on April 23, 2026. The consensus target price stands at $50.78, based on nine analyst opinions.
About Axogen, Inc.
Axogen, Inc., based in Alachua, Florida, specializes in developing and selling products for peripheral nerve regeneration and repair. The company offers a range of products like the Avance Nerve Graft and Axoguard Nerve Connector, which aid in surgical nerve repair. Led by CEO Lindsey Hartley, Axogen employs 622 people and serves hospitals and surgery centers worldwide, focusing on surgeons in various specialties.
Bottom Line
Joseph Tyndall's recent purchase of Axogen shares is part of a broader pattern of insider buying at the company. While Axogen's stock has shown significant volatility, trading near its 52-week high, the firm's focus on nerve repair technologies continues to attract interest. Investors should note that insider and institutional trades, along with analyst ratings, provide valuable insights but are not real-time indicators.
Get Axogen, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AXGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.